115 related articles for article (PubMed ID: 32916418)
41. Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
Lah TT; Nanni I; Trinkaus M; Metellus P; Dussert C; De Ridder L; Rajcević U; Blejec A; Martin PM
J Neurosurg; 2010 May; 112(5):940-50. PubMed ID: 19747051
[TBL] [Abstract][Full Text] [Related]
42. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
43. Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma.
Zhang H; Qi L; Du Y; Huang LF; Braun FK; Kogiso M; Zhao Y; Li C; Lindsay H; Zhao S; Injac SG; Baxter PA; Su JM; Stephan C; Keller C; Heck KA; Harmanci A; Harmanci AO; Yang J; Klisch TJ; Li XN; Patel AJ
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517016
[TBL] [Abstract][Full Text] [Related]
44. Genomic profile of human meningioma cell lines.
Mei Y; Bi WL; Greenwald NF; Agar NY; Beroukhim R; Dunn GP; Dunn IF
PLoS One; 2017; 12(5):e0178322. PubMed ID: 28552950
[TBL] [Abstract][Full Text] [Related]
45. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
[TBL] [Abstract][Full Text] [Related]
46. Analysis of meningiomas by methylation- and transcription-based clonality assays.
Zhu J; Frosch MP; Busque L; Beggs AH; Dashner K; Gilliland DG; Black PM
Cancer Res; 1995 Sep; 55(17):3865-72. PubMed ID: 7641206
[TBL] [Abstract][Full Text] [Related]
47. Multimodal treatment of parasagittal meningiomas: a single-center experience.
Gatterbauer B; Gevsek S; Höftberger R; Lütgendorf-Caucig C; Ertl A; Mallouhi A; Kitz K; Knosp E; Frischer JM
J Neurosurg; 2017 Dec; 127(6):1249-1256. PubMed ID: 28156245
[TBL] [Abstract][Full Text] [Related]
48. DNA-fluorescence-cytometry and prognosis (grading) of meningiomas--a study of 104 surgically removed tumors.
Spaar FW; Ahyai A; Blech M
Neurosurg Rev; 1987; 10(1):35-9. PubMed ID: 3670625
[TBL] [Abstract][Full Text] [Related]
49. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2.
Park YS; Lee JH; Harwalkar JA; Bondar J; Safayhi H; Golubic M
Adv Exp Med Biol; 2002; 507():387-93. PubMed ID: 12664615
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
51. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
Palma L; Celli P; Franco C; Cervoni L; Cantore G
Neurosurg Focus; 1997 Apr; 2(4):e3. PubMed ID: 15096007
[TBL] [Abstract][Full Text] [Related]
52. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
Palma L; Celli P; Franco C; Cervoni L; Cantore G
J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
[TBL] [Abstract][Full Text] [Related]
53. Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.
Hefti M; Holenstein F; Albert I; Looser H; Luginbuehl V
Photochem Photobiol; 2011; 87(1):235-41. PubMed ID: 21073472
[TBL] [Abstract][Full Text] [Related]
54. Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.
Bujko M; Kober P; Rusetska N; Wakuła M; Goryca K; Grecka E; Matyja E; Neska J; Mandat T; Bonicki W; Siedlecki JA
J Neurooncol; 2016 Dec; 130(3):473-484. PubMed ID: 27614886
[TBL] [Abstract][Full Text] [Related]
55. CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation.
Barbieri F; Bajetto A; Porcile C; Pattarozzi A; Massa A; Lunardi G; Zona G; Dorcaratto A; Ravetti JL; Spaziante R; Schettini G; Florio T
Ann N Y Acad Sci; 2006 Dec; 1090():332-43. PubMed ID: 17384278
[TBL] [Abstract][Full Text] [Related]
56. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
57. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.
El Shafie RA; Czech M; Kessel KA; Habermehl D; Weber D; Rieken S; Bougatf N; Jäkel O; Debus J; Combs SE
Radiat Oncol; 2018 Mar; 13(1):54. PubMed ID: 29587795
[TBL] [Abstract][Full Text] [Related]
59. Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis.
Reddy AK; Ryoo JS; Denyer S; McGuire LS; Mehta AI
Neurosurg Focus; 2019 Jun; 46(6):E3. PubMed ID: 31153148
[TBL] [Abstract][Full Text] [Related]
60. Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen.
Pizem J; Velnar T; Prestor B; Mlakar J; Popovic M
Clin Neuropathol; 2014; 33(5):354-63. PubMed ID: 25034703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
